【Objective】Finding the relative factors that influence the effect of electronic burn therapy in chronic cervicitis.【Methods】Some pathogens have been detected in 176 cases of patients with chronic cervicitis who have underwent electronic burn therapy.Some possible relative factors that influence the effect of electronic therapy in chronic cervicitis have been analysed.【Results】The relative factors include the degree of cervical erosion,character of cervical grume,degree of vaginal cleanness;puriform cervical grume,poor vaginal cleanness have higher positive rate of all kinds of pathogens.【Conclusion】Some relative pathogens should be detected and eliminated before electronic burn therapy in patients with chronic cervicitis.At least,those patients who present higher degree of cervical erosion,puriform cervical grume,poor vaginal cleanness should be treated with drug until these indexes improve before electronic burn therapy.

Despite growing prevalence and incidence, the management of gout remains suboptimal. The intermittent nature of the gout makes the long-term urate-lowering therapy (ULT) particularly important for gout management. However, patients are reluctant to take medication day after day to manage incurable occasional gout flares, and suffer from possible long-term toxicity. Therefore, a safe and easy-to-operate drug delivery system with simple preparation for the long-term management of gout is very necessary. Here, a chitosan-containing sustained-release microneedle system co-loaded with colchicine and uricase liposomes were fabricated to achieve this goal. This microneedle system was confirmed to successfully deliver the drug to the skin and maintain a one-week drug retention. Furthermore, its powerful therapeutic potency to manage gout was investigated in both acute gouty and chronic gouty models. Besides, the drug co-delivery system could help avoid long-term daily oral colchicine, a drug with a narrow therapeutic index. This system also avoids mass injection of uricase by improving its stability, enhancing the clinical application value of uricase. In general, this two-drug system reduces the dosage of uricase and colchicine and improves the patient's compliance, which has a strong clinical translation.